Event Details


Global | September 8, 2022

Aspen came into spotlight when it acquired oncology drugs after their patents expired in 2009. Following the Italian Competition Authority's decision to fine Aspen, the European Commission stepped in to consider its conduct elsewhere in Europe, reaching a settlement intended to provide guidance concerning the application of excessive pricing in the pharmaceutical sector.

The Italian and Dutch Competition Authorities have investigated and fined Leadiant Biosciences for alleged excessive pricing, and investigations in other jurisdictions remain ongoing.

In the second episode of our 'Catalyst' webinar series, we will focus on the role of Article 102 TFEU in finding excessive prices in the pharmaceutical sector, and the significant role national price regulation can play in shaping such cases and the conduct of companies supplying Europe-wide.

Video Details